FDA approves Bayer's Sunharbo to prevent repeat strokes

Blood thinners have a cruel trade-off. The ones that stop dangerous clots also make you bleed more easily. On Nov. 9, the FDA approved a drug that's supposed to break that trade-off. It's called Sunharbo, made by Bayer, and it's the first approved drug in a new class called Factor XIa inhibitors. It's meant for people who recently had a mild-to-moderate stroke or a high-risk mini-stroke, to help prevent a second one.

After a stroke, doctors want to prevent clots that could cause another one. But the drugs that do that also thin blood everywhere, which raises the risk of dangerous bleeding. That includes bleeding in the brain. In Bayer's trial, called OCEANIC-STROKE, Sunharbo cut the risk of a second stroke by 26% compared with standard care. Crucially, it didn't raise bleeding risk in that same trial. If that holds up once millions of real patients take it, this could change how doctors approach stroke prevention generally. Not just for this one drug.

Keep reading — what to watch

Will Sunharbo's no-extra-bleeding result hold up outside a controlled trial? Clinical trials pick healthier, more closely monitored patients than the real world. Doctors will be watching closely once Sunharbo reaches regular pharmacies and regular patients with other health problems. Price and insurance coverage will also decide how many stroke survivors actually get access to it. That's true no matter how good the drug is.